

Data Book

Half Year Ended September 30, 2021

Contents

Financial highlights	
■ Consolidated financial summary	1
■ Consolidated statement of financial position summary	1
■ Consolidated financial indexes	1
■ Exchange rates	1
■ Consolidated financial summary (Graph)	2
Quarterly consolidated information	
Quarterly consolidated statements of income	3
Quarterly revenue details	4
■ Revenue by business segment	4
■ Revenue by region	4
■ Revenue of major products	5
Consolidated information	
Consolidated statement of financial position	6
■ Assets	6
■ Equity and liabilities	6
Consolidated statements of cash flows	7

- FY2019: Year ended March 31, 2020
- FY2020: Year ended March 31, 2021
- FY2021: Year ending March 31, 2022

Financial highlights

■ Consolidated financial summary

(JPY millions)

	FY2019		FY2020		FY2021			
	H1	Full	H1	Full	H1	% Change	Full Forecast	% Change
Revenue	118,775	241,555	118,905	249,605	128,759	8.3	260,000	4.2
Operating profit	19,011	33,535	18,686	12,187	18,805	0.6	41,500	240.5
Net profit for the period	13,129	21,714	13,698	9,126	14,254	4.1	30,500	234.2
Dividends per share (yen)	13	27	14	28	16	14.3	32	14.3
Dividend payout ratio (%)	39.5	45.6	40.5	120.2	44.7	4.2pt	41.5	-78.5pt
Core operating profit	25,639	50,023	25,690	50,101	24,306	-5.4	52,000	3.8
Core net profit for the period	18,794	35,894	19,687	37,549	18,556	-5.7	39,000	3.9

■ Consolidated statement of financial position summary

(JPY millions)

	FY2019		FY2020		FY2021
	H1	Full	H1	Full	H1
Total assets	397,073	408,768	420,021	405,285	420,435
Total equity	295,192	302,560	315,620	309,646	319,029
Interest-bearing debt*	4,590	4,965	5,134	2,400	12,441

*Not including lease obligations

■ Consolidated financial indexes

	FY2019		FY2020		FY2021	
	H1	Full	H1	Full	H1	% Change
EPS (yen)	32.94	59.16	34.58	23.30	35.79	3.5
BPS (yen)	735.77	758.50	791.30	776.16	799.56	1.0
Debt equity ratio (times)	0.0	0.0	0.0	0.0	0.0	0.0pt
PER (times)	28.5	31.4	31.1	65.4	21.3	-5.6pt
PBR (times)	2.6	2.4	2.7	2.0	2.0	-0.7pt
ROE (%)	—	8.0	—	3.0	—	—
ROA (%)	—	5.4	—	2.2	—	—
Equity ratio (%)	74.0	74.1	74.6	76.5	76.0	1.4pt
Free cash flow (millions of yen) ^{*1}	19,162	30,719	5,402	15,004	12,592	-44.1
EBITDA (millions of yen) ^{*2}	28,980	56,899	28,255	54,756	27,513	-2.6

*1 Free cash flow = (Net cash flows from operating activities)-(Capital payments for acquisition of property, plant and equipment, and intangible assets)

*2 EBITDA = (Operating profit) - (Other income) + (Other expenses) + (Depreciation and amortization)









■ Exchange rates

(Yen)

	FY2019		FY2020		FY2021	
	H1	Full	H1	Full	H1	Full Forecast
Exchange rate: USD	108.82	108.81	106.72	105.95	110.09	105.00
: EUR	121.28	120.80	121.54	123.73	131.14	125.00
: CNY	15.77	15.64	15.21	15.61	17.05	16.50

Financial highlights

■ Consolidated financial summary (Graph)



Quarterly consolidated statements of income

■ Core basis

(JPY millions)

	FY2020					FY2021					FY2021
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
Revenue	57,563	61,342	62,881	67,819	249,605	64,986	63,773				260,000
YoY	-2.7%	2.9%	-1.1%	14.5%	3.3%	12.9%	4.0%				4.2%
Cost of sales	-24,741	-24,964	-26,192	-22,324	-98,221	-26,924	-25,943				-101,000
YoY	2.6%	3.2%	0.5%	9.0%	3.6%	8.8%	3.9%				2.8%
(Percent of revenue)	43.0%	40.7%	41.7%	32.9%	39.4%	41.4%	40.7%				38.8%
Gross profit	32,822	36,377	36,690	45,495	151,384	38,062	37,829				159,000
YoY	-6.3%	2.6%	-2.1%	17.4%	3.2%	16.0%	4.0%				5.0%
(Percent of revenue)	57.0%	59.3%	58.3%	67.1%	60.6%	58.6%	59.3%				61.2%
Operating profit	11,655	14,035	10,738	13,673	50,101	11,713	12,593				52,000
YoY	-8.9%	9.3%	-13.0%	13.5%	0.2%	0.5%	-10.3%				3.8%
(Percent of revenue)	20.2%	22.9%	17.1%	20.2%	20.1%	18.0%	19.7%				20.0%
Net profit for the period	8,807	10,880	8,653	9,210	37,549	9,026	9,530				39,000
YoY	-8.9%	19.3%	2.9%	6.0%	4.6%	2.5%	-12.4%				3.9%
(Percent of revenue)	15.3%	17.7%	13.8%	13.6%	15.0%	13.9%	14.9%				15.0%

■ IFRS

(JPY millions)

	FY2020					FY2021					FY2021
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
Revenue	57,563	61,342	62,881	67,819	249,605	64,986	63,773				260,000
YoY	-2.7%	2.9%	-1.1%	14.5%	3.3%	12.9%	4.0%				4.2%
Cost of sales	-24,741	-24,964	-26,192	-22,324	-98,221	-26,924	-25,943				-101,000
YoY	2.6%	3.2%	0.5%	9.0%	3.6%	8.8%	3.9%				2.8%
(Percent of revenue)	43.0%	40.7%	41.7%	32.9%	39.4%	41.4%	40.7%				38.8%
Gross profit	32,822	36,377	36,690	45,495	151,384	38,062	37,829				159,000
YoY	-6.3%	2.6%	-2.1%	17.4%	3.2%	16.0%	4.0%				5.0%
(Percent of revenue)	57.0%	59.3%	58.3%	67.1%	60.6%	58.6%	59.3%				61.2%
SG&A expenses	-15,551	-17,691	-19,579	-26,732	-79,554	-20,447	-19,205				-81,000
YoY	-3.1%	1.8%	0.9%	30.2%	8.4%	31.5%	8.6%				5.0%
(Percent of revenue)	27.0%	28.8%	31.1%	39.4%	31.9%	31.5%	30.1%				31.2%
R&D expenses	-5,616	-5,507	-6,530	-6,459	-24,112	-6,121	-6,218				-26,000
YoY	-9.0%	5.1%	13.8%	4.4%	3.3%	9.0%	12.9%				7.8%
(Percent of revenue)	9.8%	9.0%	10.4%	9.5%	9.7%	9.4%	9.7%				10.0%
Amortization on intangible assets associated with products	-2,448	-2,430	-2,503	-2,539	-10,650	-2,040	-2,747				-8,900
YoY	-1.2%	-1.2%	1.1%	2.1%	7.6%	-16.7%	13.1%				-16.4%
(Percent of revenue)	4.3%	4.0%	4.0%	3.7%	4.3%	3.1%	4.3%				3.4%
Other income	176	174	174	15,483	16,007	120	82				500
Other expenses	-1,367	-253	330	-39,599	-40,889	-39	-473				-1,700
Operating profit	8,016	10,670	8,581	-14,351	12,187	9,537	9,268				41,500
YoY	-13.3%	9.3%	-13.6%	—	-63.7%	19.0%	-13.1%				240.5%
(Percent of revenue)	13.9%	17.4%	13.6%	—	4.9%	14.7%	14.5%				16.0%
Finance income	530	36	450	330	1,346	590	82				900
Finance expenses	-187	-695	-264	-341	-1,488	-277	-163				-200
Share of loss of investments accounted for using equity method	—	-17	-158	-183	-358	-297	-346				1,200
Profit before tax	8,359	9,994	8,609	-14,545	11,688	9,552	8,841				41,000
YoY	-7.1%	6.3%	-18.4%	—	-63.6%	14.3%	-11.5%				250.8%
(Percent of revenue)	14.5%	16.3%	13.7%	—	4.7%	14.7%	13.9%				15.8%
Income tax expenses	-2,235	-2,420	-1,362	244	-2,562	-2,185	1,954				10,500
Net profit for the period	6,124	7,575	7,248	-14,301	9,126	7,367	6,887				30,500
YoY	-4.2%	12.4%	1.4%	—	-58.0%	20.3%	-9.1%				234.2%
(Percent of revenue)	10.6%	12.3%	11.5%	—	3.7%	11.3%	10.8%				11.7%
Owners of the company	6,189	7,624	7,304	-14,286	9,311	7,383	6,924				30,800
Non-controlling interests	-65	-50	-56	-15	-185	-15	-38				-300

Retroactive restatement of FY2020 figures:

The consolidated statement of financial position for FY2020 has been retroactively revised due to the completion of the allocation of consideration for acquisition of Eyeveance. The following figures have been adjusted: "intangible asset amortization related to products", "operating profit", "profit before tax", "income tax expenses" and "net profit". Since these items for Q3 and Q4 have not been updated, the total of each quarter of FY2020 and the figure for the full year do not match.

Quarterly revenue details

■Revenue by business segment

(JPY millions)

	FY2020					FY2021					FY2021
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
Prescription pharmaceuticals	54,336	57,151	59,030	64,171	234,687	61,008	59,363				244,000
YoY	0.2%	3.5%	-0.3%	14.8%	4.5%	12.3%	3.9%				4.0%
OTC pharmaceuticals	2,043	2,961	2,382	2,024	9,410	2,444	2,643				10,000
YoY	-45.0%	-1.2%	-24.0%	-7.5%	-21.8%	19.7%	-10.8%				6.3%
Medical devices	827	889	1,071	1,249	4,037	1,145	1,337				5,000
Others	357	341	398	375	1,471	389	431				1,000
Total	57,563	61,342	62,881	67,819	249,605	64,986	63,773				260,000
YoY	-2.7%	2.9%	-1.1%	14.5%	3.3%	12.9%	4.0%				4.2%

[Japan]

(JPY millions)

	FY2020					FY2021					FY2021
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
Prescription pharmaceuticals	35,078	36,075	38,992	45,662	155,807	38,952	36,723				156,100
YoY	4.4%	3.3%	-0.9%	11.4%	4.7%	11.0%	1.8%				0.2%
OTC pharmaceuticals	1,975	2,851	2,303	1,928	9,058	2,305	2,486				9,700
YoY	-45.7%	-2.3%	-24.7%	-8.4%	-22.7%	16.7%	-12.8%				7.1%
Medical devices	645	690	784	806	2,926	695	847				3,400
Others	317	318	358	349	1,343	369	401				800
Total	38,016	39,934	42,438	48,746	169,133	42,321	40,456				170,000
YoY	-0.7%	2.2%	-2.4%	10.3%	2.5%	11.3%	1.3%				0.5%

[Overseas]

(JPY millions)

	FY2020					FY2021					FY2021
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
Prescription pharmaceuticals	19,258	21,076	20,037	18,510	78,880	22,055	22,640				87,900
YoY	-6.8%	3.7%	0.8%	24.4%	4.1%	14.5%	7.4%				11.4%
OTC pharmaceuticals	67	110	79	96	352	139	157				300
YoY	-11.2%	40.4%	5.1%	15.1%	12.7%	106.3%	43.0%				-14.7%
Medical devices	182	199	287	443	1,111	450	489				1,600
Others	40	23	40	25	129	20	30				200
Total	19,547	21,408	20,443	19,074	80,472	22,665	23,317				90,000
YoY	-6.3%	4.1%	1.8%	27.0%	5.1%	15.9%	8.9%				11.8%

■Revenue by region

(JPY millions)

	FY2020					FY2021					FY2021
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
China	5,806	6,952	5,570	5,021	23,349	6,460	7,556				27,000
YoY	-14.0%	-0.1%	-1.6%	70.2%	4.6%	11.2%	8.7%				15.6%
Asia (China is not included)	3,953	5,244	4,117	3,902	17,216	4,600	4,457				19,000
YoY	-11.2%	21.6%	5.6%	1.8%	4.4%	16.4%	-15.0%				10.4%
EMEA	9,566	8,859	10,021	9,450	37,896	10,704	10,538				40,000
YoY	1.2%	-0.9%	-4.4%	16.7%	2.5%	11.9%	19.0%				5.6%
Americas	222	353	736	701	2,011	901	766				4,000
YoY	6.6%	2.4%	—	411.7%	173.5%	305.8%	117.3%				98.9%

Quarterly revenue details

■ Revenue of major products

(JPY millions)

Brand name (Therapeutic category)	Region	FY2020					FY2021					FY2021 Full Forecast
		Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	
Cravit (Bacterial conjunctivitis)	Total	3,291	4,286	2,874	2,200	12,650	3,063	3,797				12,147
	Japan	521	557	528	365	1,971	488	483				1,592
	China	2,186	2,760	1,661	1,321	7,927	1,754	2,661				7,859
	Asia	386	712	313	311	1,722	505	369				1,786
	EMEA	197	257	372	203	1,029	316	283				910
Tarivid (Bacterial conjunctivitis)	Total	319	598	288	222	1,427	386	305				1,215
	Japan	89	99	88	61	337	87	92				279
	China	149	179	180	176	683	213	193				688
	Asia	82	320	20	-15	406	86	20				247
Tapcom (Glaucoma)	Total	1,529	1,430	1,683	1,394	6,036	1,747	1,693				6,566
	Japan	685	651	729	539	2,604	724	688				2,403
	Asia	122	108	162	155	546	173	202				763
	EMEA	722	671	793	700	2,886	850	803				3,399
Tapros (Glaucoma)	Total	4,672	4,444	4,806	3,994	17,915	4,683	4,503				20,564
	Japan	2,372	2,233	2,417	1,687	8,709	2,281	2,118				8,738
	China	114	117	157	215	602	266	199				2,788
	Asia	461	493	468	485	1,907	490	493				2,105
	EMEA	1,725	1,602	1,763	1,606	6,696	1,646	1,693				6,933
Cosopt (Glaucoma)	Total	5,609	5,119	5,424	4,725	20,877	5,437	5,321				19,597
	Japan	2,042	1,775	1,851	1,272	6,940	1,576	1,442				5,173
	Asia	1,050	1,051	1,156	1,205	4,462	1,240	1,223				4,778
	EMEA	2,516	2,293	2,417	2,248	9,475	2,621	2,656				9,646
Timoptol *Including Timoptol XE (Glaucoma)	Total	614	517	592	472	2,196	565	518				1,859
	Japan	322	295	311	210	1,137	283	248				789
	Asia	92	27	72	73	264	78	73				294
	EMEA	200	196	209	190	794	204	197				777
Trusopt (Glaucoma)	Total	1,082	1,181	1,167	936	4,365	1,169	1,123				3,862
	Japan	350	320	331	226	1,227	310	278				1,009
	Asia	67	111	80	86	344	92	102				308
	EMEA	664	750	756	623	2,794	768	743				2,546
Eybelis (Glaucoma)	Total	589	619	734	594	2,536	823	848				3,696
	Japan	589	619	734	574	2,516	806	822				3,612
Alesion *Including Alesion LX (Allergy)	Total	3,047	4,647	4,978	20,080	32,752	5,065	4,502				32,368
	Japan	3,047	4,647	4,978	20,062	32,733	5,038	4,468				32,225
	Asia	—	—	—	19	19	28	34				143
Flumetholon (Inflammation)	Total	650	817	654	691	2,812	834	877				2,961
	Japan	242	253	249	308	1,052	222	221				924
	China	325	485	263	319	1,392	528	572				1,676
	Asia	83	79	142	64	368	84	84				361
Pirenoxine Ophthalmic Suspension (Senile cataract)	Total	974	1,081	1,042	899	3,995	1,077	1,061				4,025
	Japan	616	629	666	481	2,391	617	596				2,354
	China	189	208	184	190	771	222	209				717
Oftan Catachrom (Senile cataract)	Asia	169	244	192	227	832	238	256				954
	Total	870	196	318	446	1,830	379	503				1,767
Sodium Hyaluronate Ophthalmic Viscoelastic Preparation (Adjuvant for ophthalmic operations)	EMEA	870	196	318	446	1,830	379	503				1,767
	Total	527	558	665	439	2,189	544	497				2,414
EYLEA *1 (Intravitreal VEGF inhibitor)	Japan	527	558	665	439	2,189	544	497				2,414
	Total	16,802	16,491	17,662	13,498	64,454	18,727	17,748				65,038
Hyalein (Dry eye)	Japan	16,802	16,491	17,662	13,498	64,454	18,727	17,748				65,038
	Total	4,523	5,185	5,023	3,689	18,420	4,251	4,063				14,932
	Japan	1,815	1,789	1,972	1,392	6,967	1,721	1,602				5,893
	China	2,349	2,425	2,431	2,054	9,259	2,145	2,074				6,918
Diquas (Dry eye)	Asia	359	972	620	243	2,194	386	387				2,121
	Total	3,551	3,558	4,004	3,291	14,403	4,537	4,649				17,935
	Japan	3,012	3,069	3,540	2,663	12,283	3,402	3,249				13,249
Ikervis (Dry eye)	China	71	172	167	307	717	697	983				2,782
	Asia	468	317	297	322	1,404	438	417				1,904
	Total	939	1,137	1,260	1,192	4,529	1,656	1,356				5,553
Cationorm (Dry eye)	Asia	191	226	230	243	890	246	291				1,368
	EMEA	748	912	1,029	949	3,638	1,410	1,065				4,184
	Total	672	933	761	696	3,062	829	806				3,420
Lentis comfort (Intraocular Lens for Cataract Treatment)	Asia	71	54	74	57	256	103	82				337
	EMEA	438	586	470	475	1,969	532	536				2,315
	US	163	293	218	165	838	194	188				768
PRESERFLO MicroShunt (Glaucoma implant device)	Total	215	250	364	367	1,196	341	327				2,058
	Japan	215	250	364	367	1,196	341	327				2,058
OTC pharmaceuticals	Total	174	182	273	263	892	347	381				1,500
	EMEA	174	182	273	263	892	347	381				1,440
OTC pharmaceuticals	Total	2,043	2,961	2,382	2,024	9,410	2,444	2,643				10,000
	Japan	1,975	2,851	2,303	1,928	9,058	2,305	2,486				9,700
	Asia	67	110	79	96	352	139	157				300

*1 Co-promoted product of Bayer Yakuhin, Ltd. (MAH)

Note: Forecasts in this report are based on currently available information. Actual results may differ materially depending on a number of factors including business environment change and others. Our full-year forecasts are based on our foreign exchange assumptions. Revenue by region shows that of major countries or regions.

Consolidated statement of financial position

(JPY millions)

	FY2019		FY2020		FY2021	
	Full		Full		H1	
		%		%		%
■Assets						
Non-current assets						
Property, plant and equipment	35,601	8.7	39,489	9.7	49,082	11.7
Intangible assets	119,850	29.3	115,808	28.6	115,482	27.5
Financial assets	30,848	7.5	31,903	7.9	31,683	7.5
Retirement benefit asset	—	—	1,619	0.4	1,209	0.3
Investments from application of equity method	—	—	5,162	1.3	7,362	1.8
Deferred tax assets	2,100	0.5	2,824	0.7	2,753	0.7
Other non-current assets	1,813	0.4	2,249	0.6	1,682	0.4
Total non-current assets	190,212	46.5	199,054	49.1	209,253	49.8
Current assets						
Inventories	35,282	8.6	41,575	10.3	40,311	9.6
Trade and other receivables	86,999	21.3	95,992	23.7	86,250	20.5
Other financial assets	452	0.1	527	0.1	367	0.1
Other current assets	4,392	1.1	5,248	1.3	8,218	2.0
Cash and cash equivalents	91,430	22.4	62,888	15.5	76,036	18.1
Total current assets	218,556	53.5	206,231	50.9	211,182	50.2
Total assets	408,768	100.0	405,285	100.0	420,435	100.0
■Equity and liabilities						
Equity						
Share capital	8,366	2.0	8,525	2.1	8,538	2.0
Capital surplus	8,746	2.1	8,954	2.2	8,860	2.1
Treasury shares	-1,033	-0.3	-934	-0.2	-718	-0.2
Retained earnings	273,422	66.9	273,238	67.4	282,296	67.1
Other components of equity	13,364	3.3	20,398	5.0	20,656	4.9
Total equity attributable to owners of the company	302,865	74.1	310,181	76.5	319,632	76.0
Non-controlling interests	-305	-0.1	-535	-0.1	-603	-0.1
Total equity	302,560	74.0	309,646	76.4	319,029	75.9
Liabilities						
Non-current liabilities						
Financial liabilities	27,592	6.7	10,141	2.5	19,915	4.7
Net defined benefit liabilities	1,738	0.4	1,210	0.3	1,180	0.3
Provisions	570	0.1	600	0.1	618	0.1
Deferred tax liabilities	7,228	1.8	3,626	0.9	3,518	0.8
Other non-current liabilities	1,483	0.4	1,514	0.4	920	0.2
Total non-current liabilities	38,611	9.4	17,090	4.2	26,152	6.2
Current liabilities						
Trade and other payables	32,578	8.0	38,106	9.4	37,810	9.0
Other financial liabilities	18,777	4.6	23,739	5.9	23,357	5.6
Income tax payable	6,848	1.7	5,458	1.3	4,588	1.1
Provisions	633	0.2	819	0.2	793	0.2
Other current liabilities	8,761	2.1	10,428	2.6	8,706	2.1
Total current liabilities	67,597	16.5	78,549	19.4	75,254	17.9
Total liabilities	106,208	26.0	95,639	23.6	101,407	24.1
Total equity and liabilities	408,768	100.0	405,285	100.0	420,435	100.0

Retroactive restatement of FY2020 figures:

The consolidated statement of financial position for FY2020 has been retroactively revised due to the completion of the allocation of consideration for acquisition of Eyeveance. The following figures have been adjusted: "intangible assets", "total non-current assets", "total assets", "retained earnings", "other capital components", "total equity", "deferred tax liability", "non-current liability", "total liabilities", and "total equity and liabilities".

Consolidated statements of cash flows

(JPY millions)

	FY2019		FY2020		FY2021
	H1	Full	H1	Full	H1
I . Cash flows from operating activities:					
Net profit for the period	13,129	21,714	13,698	6,645	14,254
Depreciation and amortization	8,202	16,573	8,184	16,768	8,302
Impairment losses	—	5,825	198	40,664	48
Share of loss (profit) of entities accounted for using equity method	—	—	17	358	643
Income tax expenses	5,279	10,377	4,655	5,773	4,139
Decrease (increase) in trade and other receivables	5,449	(3,054)	6,380	(7,514)	9,885
Decrease (increase) in inventories	558	(981)	(4,126)	(4,590)	1,468
Increase (decrease) in trade and other payables	(864)	717	(404)	4,948	(338)
Increase (decrease) in provisions and net defined benefit liabilities	(474)	(1,242)	462	(176)	378
Decrease (increase) in other current assets	(1,518)	(894)	(1,751)	(407)	(2,705)
Increase (decrease) in accounts payable - bonuses	(1,319)	(678)	(811)	870	(1,516)
Other	2,345	5,149	(1,309)	(12,224)	(2,781)
Subtotal	30,786	53,506	25,193	51,115	31,777
Interest received	52	200	76	195	136
Dividends received	260	581	246	490	250
Interest paid	(92)	(190)	(82)	(159)	(102)
Income tax paid	(7,419)	(14,149)	(7,005)	(12,834)	(4,966)
Net cash flows from (used in) operating activities	23,588	39,947	18,428	38,808	27,096
II . Cash flows from investing activities:					
Payments for acquisition of investments	(121)	(398)	(2,452)	(3,384)	(536)
Proceeds from sale of investments	1,671	3,503	—	3,070	746
Payment for acquisition of shares of subsidiary	—	—	(23,834)	(23,834)	—
Payments for acquisition of investments accounted for using equity method	—	—	(5,349)	(5,349)	(2,759)
Payments for acquisition of property, plant and equipment	(2,792)	(5,824)	(1,920)	(4,139)	(9,792)
Payments for acquisition of intangible assets	(1,633)	(3,404)	(11,106)	(19,665)	(4,711)
Other	967	949	(14)	(55)	(4)
Net cash flows from (used in) investing activities	(1,908)	(5,175)	(44,734)	(53,355)	(17,057)
III . Cash flows from financing activities:					
Proceeds from long-term loans payable	588	1,477	148	307	10,000
Dividends paid	(5,182)	(10,379)	(5,592)	(11,188)	(5,596)
Repayments of lease obligation	(1,396)	(2,859)	(1,407)	(2,952)	(1,432)
Other	28	(969)	80	(2,852)	(0)
Net cash flows from (used in) financing activities	(5,962)	(12,729)	(6,771)	(16,685)	2,972
IV . Net increase (decrease) in cash and cash equivalents	15,717	22,044	(33,077)	(31,232)	13,011
V . Cash and cash equivalents at the beginning of period	70,796	70,796	91,430	91,430	62,888
VI . Effect of exchange rate changes on cash and cash equivalents	(1,542)	(1,410)	391	2,690	136
VII . Cash and cash equivalents at the end of period	84,972	91,430	58,745	62,888	76,036

Cash flow in FY2020 is the value before retroactive statement at present.